Small Pharma to Participate in November Investor and Healthcare Conferences Post published:November 29, 2022 Post category:Press Release
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028 Post published:October 31, 2022 Post category:Press Release
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio Post published:October 19, 2022 Post category:Press Release
Small Pharma Reports Fiscal Second Quarter 2023 Highlights Post published:October 15, 2022 Post category:Press Release
Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder Post published:September 19, 2022 Post category:Press Release
Small Pharma Enters Into Automatic Share Purchase Plan Post published:September 13, 2022 Post category:Press Release
Small Pharma to Participate in Upcoming September Investor Conferences Post published:September 8, 2022 Post category:Press Release
Small Pharma Announces TSXV Approval of Normal Course Issuer Bid Post published:August 18, 2022 Post category:Press Release
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study Post published:August 15, 2022 Post category:Press Release